Breaking News Instant updates and real-time market news.

ADTN

Adtran

$16.04

1.495 (10.28%)

10:56
04/18/19
04/18
10:56
04/18/19
10:56

Adtran sees Q1 revenue $154M-$158M, consensus $154.25M

Sees Q2 gross margins in "low 40%s." Sees Q1 non-GAAP operating expenses up slightly over Q1. Sees Q2 tax rate "up sequentially to high 20%s-30%. Management notes that certain items may cause material differences between expectations and actual results in Q2. Guidance provided during Q1 earnings conference call.

  • 18

    Apr

  • 07

    May

  • 08

    May

ADTN Adtran
$16.04

1.495 (10.28%)

10/18/18
NEED
10/18/18
NO CHANGE
Target $17
NEED
Buy
Adtran price target lowered to $17 at Needham on Q3 revenue slip
Needham analyst Richard Valera nudged his price target on Adtran (ADTN) lower to $17 from $18 and also lowered his FY19 EPS view to 15c from 42c after its Q3 revenues came in "light due to an explainable slip out of shipments to NBN". The analyst also notes the management's more downbeat view of its G.Fast program with AT&T (T), along with a generally more muted outlook for next year. Valera keeps a Buy on Adtran however, stating that although the stock is setting new 52-week lows on a series of disappointments, its valuation multiple of 1.1-times enterprise value to expected 2018 sales is supportive of the rating.
12/20/18
MKMP
12/20/18
NO CHANGE
Target $17
MKMP
Buy
Adtran price target lowered to $17 from $22 at MKM Partners
MKM Partners analyst Michael Genovese lowered his price target on Adtran to $17, modeling a valuation multiple of 1-times enterprise value to expected FY19 sales. The analyst also keeps his Buy rating on the stock and believes that the 40% decline in its price over the past 3 months is excessive. Genovese claims that Adtran is an "underappreciated potential beneficiary" of security related issues at Huawei while retaining its "share gains in the Cable MSO market related to Fiber Deep architecture" and ramping ups sales to NBN in Australia.
01/29/19
NEED
01/29/19
DOWNGRADE
NEED
Hold
Adtran downgraded to Hold from Buy at Needham
01/29/19
01/29/19
DOWNGRADE

Hold
Adtran downgraded to Hold at Needham on margin pressure
As previously reported, Needham analyst Richard Valera downgraded Adtran to Hold from Buy, saying that while the company posted solid Q4 results, the quarter was aided "by the re- emergence of Telmex" and warns that its shift toward international business will results in "structurally lower margins" and limited earnings power. The analyst further notes that he had previously anticipated AT&T (T) and Verizon (VZ) deals as "potentially significant" North America revenue opportunities, but now sees "little confidence either of these programs will ramp substantially over the near to medium term." Valera adds that the recent bounce in Adtran stock has taken its price to within 10% of his prior target, justifying a neutral stance.

TODAY'S FREE FLY STORIES

CTIC

CTI BioPharma

$0.95

(0.00%)

10:33
12/09/19
12/09
10:33
12/09/19
10:33
Hot Stocks
CTI BioPharma: PAC203 results show pactritinib 200mg 'well tolerated' »

CTI BioPharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
12/09/19
12/09
10:25
12/09/19
10:25
General news
Concerns over a year-end spike in the money markets »

Concerns over a year-end…

10:25
12/09/19
12/09
10:25
12/09/19
10:25
Conference/Events
JPMorgan Mexican strategist to hold an analyst/industry conference call »

Mexican Equity Strategist…

10:25
12/09/19
12/09
10:25
12/09/19
10:25
Conference/Events
UBS alternative energy windham to hold an analyst/industry conference call »

Alternative Energy &…

ZG

Zillow

$40.54

-0.18 (-0.44%)

, SPCE

Virgin Galactic

$8.20

0.92 (12.64%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

ZG

Zillow

$40.54

-0.18 (-0.44%)

SPCE

Virgin Galactic

$8.20

0.92 (12.64%)

PAA

Plains All American

$17.29

-0.01 (-0.06%)

PAGP

Plains GP Holdings

$17.37

0.01 (0.06%)

SSKN

Strata Skin Sciences

$2.20

0.04 (1.85%)

ZYME

Zymeworks

$41.25

-0.45 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 30

    Dec

  • 04

    Feb

MMM

3M

$169.82

-1.675 (-0.98%)

, PNC

PNC Financial

$153.68

-0.13 (-0.08%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

MMM

3M

$169.82

-1.675 (-0.98%)

PNC

PNC Financial

$153.68

-0.13 (-0.08%)

M

Macy's

$14.96

-0.19 (-1.25%)

CVX

Chevron

$117.18

-0.8 (-0.68%)

HBIO

Harvard Bioscience

$2.83

-0.12 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 15

    Jan

QRVO

Qorvo

$109.72

3.04 (2.85%)

, SWKS

Skyworks

$104.55

3.15 (3.11%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

QRVO

Qorvo

$109.72

3.04 (2.85%)

SWKS

Skyworks

$104.55

3.15 (3.11%)

FATE

Fate Therapeutics

$19.69

6.05 (44.35%)

WING

Wingstop

$84.26

4.04 (5.04%)

HUN

Huntsman

$23.31

0.48 (2.10%)

FTV

Fortive

$74.68

1.82 (2.50%)

DOW

Dow Inc.

$53.29

0.04 (0.08%)

KRA

Kraton

$23.96

0.92 (3.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 13

    Dec

  • 18

    Dec

  • 19

    Dec

TPR

Tapestry

$25.85

0.305 (1.19%)

10:20
12/09/19
12/09
10:20
12/09/19
10:20
Options
Upside February calls see heavy trading in Tapestry »

Upside February calls see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWTX

SpringsWorks Therapeutics

$28.00

3.01 (12.04%)

, GSK

GlaxoSmithKline

$45.64

0.13 (0.29%)

10:19
12/09/19
12/09
10:19
12/09/19
10:19
Hot Stocks
SpringsWorks reports Glaxo presentation of preclinical data on nirogacestat »

SpringWorks Therapeutics…

SWTX

SpringsWorks Therapeutics

$28.00

3.01 (12.04%)

GSK

GlaxoSmithKline

$45.64

0.13 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
12/09/19
12/09
10:17
12/09/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGIO

Agios Pharmaceuticals

$44.49

3.56 (8.70%)

10:16
12/09/19
12/09
10:16
12/09/19
10:16
Hot Stocks
Agios Pharmaceuticals reports new data from DRIVE PK Phase 2 study »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 13

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
12/09/19
12/09
10:16
12/09/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$22.25

7.85 (54.51%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Hot Stocks
Forty Seven announces preclinical proof-of-concept data for FSI-174 »

Forty Seven announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

NKTR

Nektar

$22.00

1.55 (7.58%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Hot Stocks
Nektar announces presentation of data for NKTR-255 at ASH »

Nektar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

UPS

UPS

$116.87

-0.67 (-0.57%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Hot Stocks
UPS reports expansion of UPS Worldwide Express, Express Plus across 40 countries »

UPS announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$60.30

-0.69 (-1.13%)

10:15
12/09/19
12/09
10:15
12/09/19
10:15
Options
Centene put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CNST

Constellation Pharmaceuticals

$47.50

3.4 (7.71%)

10:14
12/09/19
12/09
10:14
12/09/19
10:14
Hot Stocks
Breaking Hot Stocks news story on Constellation Pharmaceuticals »

Constellation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

ACHN

Achillion

$6.19

0.02 (0.32%)

10:14
12/09/19
12/09
10:14
12/09/19
10:14
Hot Stocks
Achillion reports 'positive' data from Phase 2 danicopan, eculizumab study »

Achillion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ATRA

Atara Biotherapeutics

$14.24

0.25 (1.79%)

10:12
12/09/19
12/09
10:12
12/09/19
10:12
Hot Stocks
Atara reports updated long-term clinical results from Tab-cel EBV+ PTLD study »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLOB

Globant

$102.78

-0.525 (-0.51%)

10:12
12/09/19
12/09
10:12
12/09/19
10:12
Conference/Events
Globant management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 11

    Dec

  • 16

    Jan

CNST

Constellation Pharmaceuticals

$47.50

3.4 (7.71%)

10:12
12/09/19
12/09
10:12
12/09/19
10:12
Hot Stocks
Constellation Pharmaceuticals provides update on MANIFEST clinical trial »

Constellation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

DTIL

Precision BioSciences

$18.00

-1.66 (-8.44%)

10:11
12/09/19
12/09
10:11
12/09/19
10:11
Hot Stocks
Breaking Hot Stocks news story on Precision BioSciences »

Precision BioSciences Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

MTEM

Molecular Templates

$12.23

(0.00%)

10:10
12/09/19
12/09
10:10
12/09/19
10:10
Hot Stocks
Molecular Templates announces presentations of two posters at ASH »

Molecular Templates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAR

Avis Budget

$31.72

0.545 (1.75%)

10:10
12/09/19
12/09
10:10
12/09/19
10:10
Conference/Events
Avis Budget management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

XNCR

Xencor

$41.27

0.25 (0.61%)

10:08
12/09/19
12/09
10:08
12/09/19
10:08
Hot Stocks
Xencor presents Initial Data from Phase 1 Study of XmAb 13676 »

Xencor announced initial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.